重组人补体C3a 重组蛋白

特别声明：本产品及我公司所售其他产品均为科研类试剂产品，严禁用于药物、YL及其他非科研用途。

北京百奥莱博专注于生命科学和生物技术领域，致力于为客户提供包括重组人补体C3a 重组蛋白在内的一系列分子生物学试剂产品，并提供一系列相关的技术服务。

名称：重组人补体C3a 重组蛋白
编号：JN1557
规格：10μg|50μg|500μg|1mg
英文名：Recombinant Human Complement Component C3a
品Pai：百奥莱博
产地：北京
本品由我们的大肠杆菌表达系统制备而成，目的基因编码的Ser672-Arg748表达纯化得来。

Complement Component C3a质量控制：＞95%(还原性SDS-PAGE)

Complement Component C3a制剂：冻干品

Complement Component C3a保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

Complement Component C3a复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于Complement Component C3a ：
Complement is defined as key part of innate immunity and as the first line of defense in the fight against invading pathogens. Complement 3 (C3) is the most abundant component of the complement cascade and the convergent point for all three major complement activation pathways: namely classical, alternative and mannose-binding lectin pathways. Complement activation leads to the formation of the C3 convertase, which cleaves C3 into the key effector molecules, C3a (anaphylatoxin) and C3b (opsonin) which then drive microbe removal. By binding to C3a receptor (C3aR), C3a exhibits potent anaphylatoxin activity, including increased vascular permeability, triggering degranulation of mast cells, inflammation, and activating leukocytes.

除重组人补体C3a 重组蛋白外，我公司正在打折促销以下产品：
RFT004 1kb plus DNA ladder(300～10000bp)
KFS133 神经元示踪剂—真蓝 true blue
ALH141 植物基因组DNA快速提取试剂盒 Plant genomic DNA Extraction Kit
YT463 C端BFP标签融合蛋白质粒(蓝色荧光蛋白) C-BFP plasmid（with CMV promoter）
BTN81214 Tricine-SDS PAGE阳极电泳液(干粉) Tricine-SDS-PAGE Cathod Buffer
BTN60501 一管式拭子DNA提取试剂盒 One-tube swab DNA extraction kit
SV1124 Tma 核酸内切酶 III Tma nucleic acid enzyme III
YT096 抗荧光淬灭PVP封片液 Antifade Polyvinylpyrrolidone Mounting Medium
BTN120653A 填入法DNA末端标记试剂盒 Fill-in DNA End Labeling Kit
SY0416 36mm透析袋(透析分子量14kDa) Dialysis Tube MD44 (Mw14,000)
SV0263 BstUI限制性内切酶 BstUI Restriction Endonuclease
KFS377 活性氧ROS检测荧光探针-DHE,红300/610
SY0624 植物组培KJ剂 Plant Preservative Mixture (PPM)
SY0055 鸟苷三磷酸溶液(100 mM)(GTP) GTP Solution(100 mM)
BTN131087 AP标记亲和素 AP-Avidin
KFS031 即用型免疫组织化学SP试剂盒(Mouse)
重组人补体C3a 重组蛋白关键词：重组补体C3a,重组人补体C3a蛋白,Recombinant Human Complement Component C3a,JN1557,百奥莱博


·重组小鼠Exostosin-like 2(EXTL2)
编号：JN1446
英文名称：Recombinant Mouse Exostosin-like 2
规格：10μg|50μg|500μg|1mg
本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Asn43-Met330在N端含有His标签。

Exostosin-like 2质量控制：＞95%(还原性SDS-PAGE)

Exostosin-like 2制剂：冻干品

Exostosin-like 2保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

Exostosin-like 2复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于Exostosin-like 2 ：
Exostosin-like 2 (EXTL2) is a member of the exostosin (EXT)-related family which contains five members: EXT1, EXT2, EXTL1, EXTL2, and EXTL3. Studies have shown that EXT gene family members have the activities of heparan sulfate-synthesizing glycosyltransferases. EXT1 and EXT2, which have been identified as causal genes for hereditary multiple exostoses, have HS-GlcAT-II and GlcNAcT-II activities. EXTL1 has GlcNAcT-II activity and EXTL3 has GlcNAcT-I and -II activities. EXTL2 has GlcNAcT-I and N-acetylgalactosaminyltransferase activities, and transfers a GlcNAc residue to the tetrasaccharide linkage region when this region is phosphorylated by a xylose kinase 1 (FAM20B) and thereby terminate chain elongation. In mice, lack of EXTL2 causes glycosaminoglycan (GAG) overproduction and structural changes of GAGs associated with pathological processes.


重组人补体C3a 重组蛋白关键词：重组补体C3a,重组人补体C3a蛋白,Recombinant Human Complement Component C3a,JN1557,百奥莱博


·重组人α-半乳糖苷酶
编号：JN0529
英文名称：Recombinant Human alpha-Galactosidase
规格：10μg|50μg|500μg|1mg
本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Leu32-Leu429在C端含有His标签。

α-Galactosidase质量控制：＞95%(还原性SDS-PAGE)

α-Galactosidase制剂：液体

α-Galactosidase保存：收到货后请置于-20℃，可保存6个月，避免反复冻融。

关于α-Galactosidase：
α-Galactosidase A is a homodimeric glycoprotein that belongs to the glycosyl hydrolase 27 family. It is a lysosomal enzyme and used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. α-Galactosidase A can hydrolyze terminal α-galactosyl moieties from glycolipids and glycoproteins and catalyze the hydrolysis of melibiose into galactose and glucose. Defects α-Galactosidase A are the cause of Fabry disease (FD) which is a rare X-linked sphingolipidosis disease with glycolipid accumulates in many tissues. The disease consists of an inborn error of glycosphingolipid catabolism. FD patients show systemic accumulation of globotriaoslyceramide (Gb3) and related glycosphingolipids in the plasma and cellular lysosomes throughout the body. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease.

我公司正在优惠促销重组蛋白等系列产品，期待您的咨询选购重组人补体C3a 重组蛋白。